abiraterone acetate, Janssen Biotech, MAGNITUDO, mCRPC, Niraparib
Niraparib et abiraterone acetatis plus valitudinis ab FDA approbatur quia BRCA metastatica castratio-repugnans cancer prostatae
Augusti 2023: Certa dosis compositionis niraparib et abirateronis acetatis (Akeega, Janssen Biotech, Inc.), una cum valium approbata est Administratione Cibus et medicamentis adultis aegris castratione-resista.
Janssen Biotech, MONUMENTAL-1, multa myeloma, Talquetamab-tgvs, Talvey
Talquetamab-tgvs approbationem acceleratam accepit pro relapso vel refractorio multiple myeloma
Augusti 2023 : Talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) Approbatio accelerata est a Administratione Cibus et medicamentis ad curationem adultorum cum relapso vel refractorio multiplex myeloma qui passi sunt ..
Janssen Biotech, MajesTEC-1, NCT03145181, teclistamab-cqyv, Tecvayli
Teclistamab-cqyv approbatur a FDA pro relapsus vel refractorio multiplex myeloma .
Novembris 2022 : Prima bispecifica B-cellula maturationis antigenii (BCMA) directa CD3 T-cellula sponsionis, teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), approbatio accelerata est Cibus et medicamentis ad administrationem adultorum pat.
CAR-T therapies, chimarico antigen receptores, Sinis, ciltacabtagen autoleucel, Janssen Biotech, Legenda biotech
CARVYKTI (ciltacabtagne autoleucel), BCMA Directed CAR-T Therapy, probat FDA US accipit pro curatione aegrorum adultorum cum relapso vel refractorio multiplex myeloma.
March 2022: Secundum Johnson & Johnson, therapia a societate eiusque Sinarum fundata in societate legenda Biotech Corp elaborata est ut quaedam cancri albi sanguinis cellulae cancri a Cibus et medicamentis administrati US approbata sit.
TNF, CARVYKTI, ciltacabtagen autoleucel, agente immunomodulatory, Janssen Biotech, proteasome Matrix
Ciltacabtagen autoleucel approbatur pro relapsus vel refractorio multiplex myeloma
Martii 2022: Post quattuor vel plures priores lineas therapiae, inhibitor proteasome (PI), agens immunomodulatorius (IMiD), et anti-CD38 monoclonalis anticorpus, Cibus et medicamentum Administration approbavit ciltacabtagne au.
Amgen, carfilzomib', Darzalex Faspro, dexamethasone, Janssen Biotech, Kyprolis, multa myeloma
Darzalex faspro, kyprolis, et dexamethasone approbatur a FDA pro myeloma multiplex.
March 2022: Daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) et carfilzomib (Kyprolis, Amgen, Inc.) plus dexamethasone a Cibus et medicamentis administrationis adultis aegris relap .
Daratumumab, Darzalex Faspro, dexamethasone, Hyaluronidase-fihj, Janssen Biotech, pomalidomide
Daratumumab hyaluronidase, et fihj plus pomalidomide dexamethasone, et sunt approbata per FDA quod curatio nam ex multa myeloma
Augusti 2021 : Daratumumab et hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) Cibus et medicamentis Administrationis in compositione cum pomalidomide et dexamethasone adultis aegris cum multiplici meo.